Blarcamesine Demonstrates Promising Results in Parkinson’s Disease Dementia Study
Anavex Life Sciences has released new data from a 48-week extension of its phase 2 study, highlighting the safety and efficacy of its investigational agent, ANAVEX2-73, also known as blarcamesine, in treating Parkinson’s disease dementia (PDD). The study, officially titled ANAVEX2-73-PDD-EP-001, encountered initial delays due to the COVID-19 pandemic, which resulted in a reduced enrollment […]